Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation 1,2 . Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model 3 and human biopsies 4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus 5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
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Alterations in the phosphoinositide 3-kinase (PI3K) pathway have been reported in a high percentage of human cancers 6, 7 . We sought to identify metabolic requirements of prostate cancer taking advantage of a faithful genetically engineered mouse model of this disease driven by loss of Pten 3 , a negative regulator of the PI3K pathway that is frequently downregulated in this tumour type 6, 8 . First, we performed high-throughput quadrupole time-of-flight mass spectrometry (q-TOF-MS) to examine metabolic alterations at two time points (3 and 6 months, onset of prostate intraepithelial neoplasia (PIN) and invasive prostate carcinoma, respectively) (Extended Data Table 1) . We did not observe significant influence of the prostate lobe or the time point of analysis, and after precluding significant alterations in candidate metabolic pathways, we focused on metabolites consistently and significantly altered in all conditions (Extended Data Fig. 1d , e and Supplementary Table 2 ). We identified 72 unique metabolites (73 assigned ions) fulfilling the criteria (Fig. 1a and Supplementary Table 1 ). Pathway enrichment analysis in this set did not show significantly altered pathways including a considerable number of metabolites (Supplementary Table 3 ). Strikingly, representation in waterfall plot revealed an increase in polyamine-synthesis-related metabolites in Pten pc−/− mice (Fig. 1b) . These results were validated in this genetically engineered mouse model and human prostate cancer tissues by quantitative liquid chromatography (LC)/MS (Extended Data Fig. 1f , g and Supplementary Table 4) .
To determine how metabolic rewiring affects polyamine dynamics, we set up 13 C-labelling metabolic analysis to trace the fate of l-methioninederived carbons in vivo (Extended Data Fig. 2a) . Next, we injected [U- Table 5) . Importantly, the increase of SAM decarboxylation (elevated dcSAM/SAM ratio) in both mouse and human pathological tissues strongly suggested that the enzyme that catalyses this reaction (S-adenosylmethionine decarboxylase 1, AMD1) is potentially responsible for the metabolic changes observed in prostate cancer (Fig. 1d-f) .
To address the contribution of dcSAM production to cell oncogenicity in prostate cancer, we ectopically expressed AMD1 in cell lines from Figure 2 | Genetic and pharmacological AMD1 modulation affects prostate cancer oncogenicity. a-c, Impact of ectopic Myc-AMD1-HA expression (a, representative of three independent experiments) on dcSAM abundance (b, n = 5 independent experiments) and anchorageindependent growth (c, n = 4 independent experiments) in DU145 cells in vitro. Mock, empty vector. Myc-AMD1-HA, Myc and haemagglutinin (HA)-tagged AMD1 ectopic expression. Mean ± s.e.m. d, Impact of ectopic Myc-AMD1-HA expression on tumour mass in DU145 xenografts grown for 43 days (mock, n = 8 tumours; Myc-AMD1-HA, n = 7 tumours). Box-and-whisker plot. e-g, Effect of doxycycline (dox)-inducible (100 ng ml −1 ; a minimum of 72 h) AMD1 silencing (sh3-sh5) on AMD1 protein expression (e, representative of three independent experiments), dcSAM abundance (f, n = 3 independent experiments), and anchorage-independent growth (g, n = 4 independent experiments) in DU145 cells. Dashed line in g indicates relative cell number of noninduced cells. No dox, without doxycycline treatment; Dox, doxycyclineinduced (100 ng ml −1 ) condition; sh, short hairpin RNA. Mean ± s.e.m. h, Impact of inducible AMD1 silencing on tumour growth rate of established DU145 xenografts (tumour numbers: sh3 no dox, n = 12; sh3 dox, n = 14; sh4 no dox, n = 10; sh4 dox, n = 7; sh5 no dox, n = 10; sh5 dox, n = 11). Growth rate was inferred from the linear regression calculated for the progressive change in tumour volume of each individual tumour during the period depicted in Extended Data Fig. 3q -s. Box-and-whisker plot. i, j, Effect of pharmacological AMD1 inhibition with SAM486A on anchorage-independent growth (i, n = 3 independent experiments) and dcSAM abundance (j, n = 3 independent experiments) in DU145 cells. Mean ± s.e.m. k, Impact of SAM486A treatment for 14 days (5 mg per kg (body weight) per day, 5 days per week) on tumour growth rate of established DU145 xenografts (vehicle, n = 11 tumours; SAM4856A, n = 10 tumours). Growth rate was inferred from the linear regression calculated for the progressive change in tumour volume of each individual tumour during the period depicted in Extended Data Fig. 4i . Box-andwhisker plot. * P < 0.05; * * P < 0.01; * * * P < 0.001. One-tailed Student's t-test was used for cell line data analysis (b, c, f, g, i, j) and one-tailed Mann-Whitney U-test for xenografts (d, h, k). this tumour type. AMD1 is produced as a pro-enzyme (proAMD1), which is subject to self-cleavage and heterotetramerization, resulting in the active enzyme 9 . After validation of a polyclonal antibody for the detection of proAMD1 and AMD1 (Extended Data Fig. 3a, b) , we generated prostate cancer cells over-expressing AMD1, which resulted in increased dcSAM abundance (Fig. 2a, b) . Interestingly, this perturbation increased foci formation, anchorage-independent growth, and in vivo tumour growth (Fig. 2c, d and Extended Data Fig. 3c-f) .
If AMD1 activity is essential for prostate cancer cell function, targeting this enzyme would represent an attractive therapeutic strategy. To test this notion, we generated and validated three AMD1-targeting doxycycline-inducible and two constitutive short hairpin RNAs (shRNAs) (Fig. 2e and Extended Data Fig. 3g-j) , which resulted in a profound reduction in dcSAM levels, the inhibition of two-imensional and anchorage-independent growth, and tumour growth in vivo (Fig. 2f-h and Extended Data Fig. 3k-t) . We excluded doxycycline-dependent (Extended Data Fig. 3u, v) and off-target effects of the shRNA (by ectopic expression of shRNA-resistant wild type and non-processable (S229A 10 ) AMD1 mutants) (Extended Data Fig. 4a-c) . Of note, we did not observe a contribution of MTAP 11-14 or 5′ -methylthioadenosine (MTA, a product of dcSAM metabolism to produce polyamines) to the effect of AMD1 inhibition (Extended Data Fig. 4d-f) .
A pharmacological inhibitor of AMD1, SAM486A, has been designed and evaluated in pre-clinical and clinical settings [15] [16] [17] [18] . Pharmacological AMD1 inhibition recapitulated the biological consequences of genetic silencing, in the absence of overt toxicity in vivo (Fig. 2i-k, Extended Data Fig. 4g -k and Supplementary Table 6) . Our results collectively demonstrate that AMD1 activity is required for prostate cancer oncogenicity.
We next sought to elucidate the mechanism underlying the production of dcSAM. Interestingly, AMD1 protein levels were increased in prostate tissue from Pten pc−/− mice in the absence of transcriptional modulation, consistent with messenger RNA (mRNA) analysis in human prostate cancer data sets ( Fig. 3a and Extended Data Fig. 5a-c) . To ascertain whether this phenotype was a direct consequence of the loss of PTEN, we analysed PTEN-deficient prostate cancer cells (LNCaP). Re-expression of yellow fluorescent protein (YFP)-PTEN WT , but not catalytically inactive YFP-PTEN C124S , in these cells resulted in the reduction in AMD1 protein levels (Extended Data Fig. 5d ) 19 . Further dissection of the PI3K-mTORC1 pathway revealed that only mTORC1 blockers among various signalling inhibitors decreased proAMD1 and AMD1 protein abundance (without consistent effects on mRNA expression; Fig. 3b and Extended Data Fig. 5e-h ). The regulation of this enzyme by mTORC1 was validated upon genetic modulation of positive and negative regulators of the complex, RAPTOR and TSC2, respectively (Extended Data Fig. 5e , i, j). Importantly, mTORC1 inhibitor-elicited AMD1 downregulation was accompanied by a decrease in dcSAM production and polyamine synthesis (Fig. 3c, d ). Of interest, spermidine supplementation in rapamycin-treated PC3 cells (PTEN-deficient) elicited a significant (albeit small) increase in cell number (Extended Data Fig. 6a ).
To ascertain the requirement of mTORC1 activation for dcSAM accumulation in vivo, we treated Pten pc−/− mice with the rapamycin-derivative RAD001 and found that Amd1 and dcSAM abundance was reduced in line with the inhibition of mTORC1 in prostate tissue ( ) and Amd1 protein expression (e, n = 3 mice), and dcSAM abundance (f, n = 5 mice), in prostate tissue extracts from Pten pc−/− mice. Data in f are mean ± s.e.m. * P < 0.05; * * P < 0.01; * * * P < 0.001. Asterisks in western blots indicate non-specific bands; arrows indicate specific bands. One-tailed Student's t-test (c, d, f) was used. , including translation initiation, p70S6K, 4EBP, and macro-autophagy (since DU145 cells lack functional ATG5 (ref. 24) but retain the mTORC1-dependent regulation of AMD1) (Extended Data Fig. 7f-i) . Interestingly, we found that mTORC1 inhibition-dependent decrease in AMD1 (wild type and S229A) protein levels was rescued by the proteasome inhibitor MG132 (Fig. 4a and Extended Data Fig. 8a, b) . To elucidate the molecular link between mTORC1 activity and proAMD1 stability, we performed a phosphoproteomic analysis on ectopic proAMD1/ AMD1 and identified a single phosphorylated residue (S298) on the pro-enzyme and enzyme (TVLApSPQKIEGFK) (Extended Data Fig.  8c ) that was compatible with a consensus mTORC1 site 25 . Importantly, treatment for 6 h with rapamycin or Torin-1 reduced the phosphorylation of S298 in the pro-enzyme (and the ratio phospho-proAMD1/ total proAMD1) but not the enzyme, leading us to hypothesize that S298 phosphorylation could be controlled by mTORC1 and promote proAMD1 stability (Fig. 4b and Extended Data Fig. 8d-f) . We evaluated the stability of proAMD1 after treatment for 2 h with Torin-1 (before the detection of any effect on pro-enzyme abundance) and found reduced half-life upon mTORC1 inhibition (Extended Data Fig. 8g-k) . To establish the contribution of S298 phosphorylation in the regulation of proAMD1 stability, we inactivated this phosphorylation site (S298A). As predicted, non-phosphorylated proAMD1 S298A exhibited decreased half-life, and this parameter was augmented upon inhibition of the proteasome (Extended Data Fig. 9a-c) . These results support the notion that mTORC1 activity promotes proAMD1 stability, at least in part, through the regulation of its phosphorylation in S298, hence allowing enzyme processing and activity. In vitro mTORC1 kinase assay with glutathione S-transferase (GST)-proAMD1 S229A did not show significant activity towards proAMD1 phosphorylation in these conditions, suggesting either that mTORC1 does not directly phosphorylate S298, or that additional cellular conditions (for example, biochemical conditions, adaptor or intermediary proteins, subcellular compartments) are required for mTORC1 to phosphorylate proAMD1 (Extended Data Fig. 9d ). It is worth noting that our data do not rule out additional mechanisms downstream of mTORC1 regulating proteasome-mediated protein degradation 23, 26 . To extend this mechanistic link to human prostate cancer, we extracted protein from well-diagnosed benign prostate hyperplasia (BPH) and prostate cancer specimens 4 (Supplementary Table 4 ). The results revealed that AMD1 was selectively more abundant in prostate cancer specimens exhibiting high mTORC1 activity, and that the phosphorylation of p70S6K significantly correlated with the levels of AMD1 (correlation coefficient R = 0.81; Fig. 4c and Extended Data Fig. 9e ). mTORC1 inhibitors are currently used to treat certain tumours (despite the unpredicted inefficacy in many others) 27 , and previous work by us has contributed to defining the pharmaco-dynamic properties of everolimus in individuals with advanced cancers of different . Strikingly, we observed a predominant decrease (64% of cases) in AMD1 immunoreactivity in 14 biopsies obtained from patients treated with this drug relative to a biopsy of the same lesion before treatment (Fig. 4d, Extended Data Fig. 9f and Supplementary Table 8) . When we stratified patients on the basis of the anti-proliferative response achieved after everolimus therapy (responders: differential KI67 H score, Δ H < 0, n = 6 specimen pairs; non-responders: differential KI67 H score, Δ H ≥ 0, n = 4 specimen pairs; where Δ H = (H score on therapy) -(H score pre-therapy)), we found that only AMD1 (among all targets analysed) presented significantly decreased immunoreactivity in responders (Fig. 4e and Extended Data Fig. 9g) .
Polyamine production is a hallmark of highly proliferating cells 30 , but their regulation by oncogenic signals remains largely unknown. Our results demonstrate that increased polyamine synthesis is associated with oncogenic signalling in prostate cancer. The regulation of AMD1 production and dcSAM synthesis downstream of mTORC1 described herein provides a mechanistic explanation for the control of this metabolic program (Extended Data Fig. 9h ). AMD1 is an unprecedented metabolic target of this protein complex and supports its role in cancer cell proliferation. Importantly, the control of dcSAM and polyamine synthesis is relevant beyond the cancer scenario, and suggests that physiological and developmental processes that require active cell proliferation might be tightly associated with the regulation of AMD1 and polyamine synthesis downstream of mTORC1.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 31 , injecting 4 × 10 6 (AMD1 silencing) or 4 × 10 6 (AMD1 ectopic expression) cells with Matrigel (BD Biosciences) per condition in two flanks per mouse. Doxycycline was administered in vivo in the food pellets (Research diets, D12100402). Genetically engineered mouse model experiments were performed in a mixed background as reported 32 . The Pten lox conditional knockout allele has been described elsewhere . At CNIO, TRAMP mice originally provided in FVB/NJ genetic background were backcrossed to a C57BL/6 background by successive mating of (T/+ ) male-mice to (+ /+ ) C57BL/6 female-mice and then maintained in a C57BL/6 background.
To address the potential undesirable effects of systemic AMD1 inhibition, we administered SAM486A intraperitoneally (5 mg per kg (body weight) per day, 5 days per week) for 17 days in immunocompetent C57BL/6 mice. We measured body and organ weight, blood biochemistry, haematocrit, and white blood cell count (information provided in Supplementary Table 6 ). Terminal blood harvest was performed intracardially after CO 2 inhalation-based euthanasia. For non-terminal harvest, a facial vein blood sample was obtained by puncture with a sterile 4 mm lancet (MEDIpoint, USA). For plasma preparation, blood was deposited in tubes with dipotassium EDTA (Microtainer, Becton Dickinson, Franklin, New Jersey, USA) (for haematocrit and FACS analysis) or heparinized tubes (10 μ l, 1 U μ l −1 ) (for plasma metabolomics). For haematocrit analysis, blood samples were analysed using an Abacus Junior Vet analyser (Diatron, Hungary) according to the manufacturer's guidelines. For blood biochemistry, a Selectra Junior Spinlab 100 analyser (Vital Scientific, Dieren, The Netherlands) was used. A calibrated control was run before each use and was within established ranges before analysing samples. For white blood cell analysis, the spleen of SAM486A or saline-treated mice was grinded by using a syringe plunger and passing the cells through a 70 μ m cell strainer; cellular composition was evaluated by flow cytometry, using the following antibodies: CD4, CD8, B220, Ly6C, F4/80, GR-1, CD25, CD11b, CD44, CD73, FR4, Nrp-1 (Miltenyi Biotec).
Purification and activation of mouse splenic CD4
+ T cells. To address the toxicity of SAM486A, we purified CD4 T cells from the spleen of C57BL/6 mice by negative selection using a CD4 purification kit following the manufacturer's instructions (Miltenyi Biotec, Auburn, California, USA). Five hundred thousand CD4 T cells were activated in TexMACS Medium (Miltenyi Biotec) with platebound anti-CD3 (5 μ g ml ) and soluble anti-CD28 (1 μ g ml ) in the presence of vehicle or SAM486A (1 μ M) for 16 and 96 h and assessed for interleukin(IL)-2 production by capture enzyme-linked immunosorbent assay (ELISA) (R&D Systems, MAB702). To analyse the effect of SAM486A on T-cell proliferation, purified CD4 T cells were recovered 4 days after activation and treatment and counted in a haemocytometer chamber. Immunization with ovalbumin. To address the effect of SAM486A on immune cell proliferation in vivo, we administered SAM486A intraperitoneally (5 mg per kg (body weight) per day, 5 days per week) for 17 days in immunocompetent C57BL/6 mice, and then immunized them subcutaneously with 50 μ g ovalbumin in complete Freund's adjuvant and kept on treatment. After 2 weeks, the mice were analysed for ovalbumin-specific serum immunoglobulin-G(IgG) andimmunoglobulin-M(IgM) levels by ELISA ) were purchased from LC Laboratories (rapamycin, PD0325901), Sigma (CHX, PF47, HCQ, spermidine, MTA), Calbiochem (SB203580), and Tocris (Torin-1, DFMO, SP600125). RAD001 was purchased from Selleckchem and administered 6 days per week by oral gavage (prepared in 1.5% NMP/98.5% PEG) at 10 mg per kg (body weight). SAM486A was provided by Novartis and prepared in water (in vitro) or saline solution (in vivo, 5 mg per kg (body weight) per day intraperitoneally Monday-Friday). [U-
13
C 5 ] l-methionine was purchased from Cambridge Isotope Laboratories and administered intravenously at a final concentration of 100 mg kg in vitro (with dialysed FBS). Doxycycline was purchased from Sigma and used at 500 ng ml −1 for overexpression of YFP-PTEN, 100 ng ml −1 for silencing of AMD1, and 250 ng ml −1 for silencing of RAPTOR and TSC2. shRNAs against AMD1 were purchased from Sigma (TRCN0000078462: sh3; TRCN0000078460: sh4, TRCN0000078461: sh5) and the control shRNA sequence i nc lu ded ( CCGGC AACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTG) 34 . shRNAs against 4EBP1 and 4EBP2 were provided by N. Sonenberg 35 . Sub-cloning of shRNA AMD1 into pLKO-Tet-On vector was done by introducing AgeI and EcoRI in the 5′ end of top and bottom shRNA oligonucleotides respectively (TET-pLKO puro was a gift from D. Wiederschain 36 , Addgene plasmid 21915). Myc-AMD1-HA-expressing vector was generated starting from the open reading frame obtained from PlasmID Harvard (https://plasmid.med.harvard.edu/ PLASMID/Home.xhtml) and cloned into a modified retroviral pLNCX vector harbouring BglII-SalI sites (cloned with BamHI-SalI). RNA interference (RNAi)-resistant versions of AMD1 were generated using overlap extension PCR and cloned into a lentiviral backbone derived from vector pLenti-Cas9-blast (Cas9 removed; lentiCas9-Blast was a gift from F. Zhang, Addgene 52962; ref. 37) using a HiFi Assembly Kit (NEB). The resulting vectors expressed AMD1-HA-2A-blast (wild type or S229A) with the AMD1-HA portion being excisable using BshT1-BamH1. The target of AMD1 shRNA3 (5′-gtctccaagagacgtttcatt-3′ ) was changed to an RNAi-resistant version (5′-gtGAGcaaACGTAGAttTatCtt-3′ ). Cloning details are available upon request. All clones were sequence-validated. Site-directed mutagenesis for generation of AMD1 S229A and AMD1 S298A was performed using an Agilent QuikChange II Site-Directed Mutagenesis Kit. YFP-PTEN-expressing lentiviral constructs were described in ref. ) and then seeding for cellular or molecular assays in the presence of doxycycline. Western blot was performed as previously described 38 and run in Nupage gradient precast gels (Life Technologies) in MOPS or MES buffer (depending on the proteins analysed; note that the migration pattern of molecular mass markers varies in these two buffers). Anti-AMD1 was from Proteintech (11052-1-AP). Anti-RpS6 S240/244 , anti-RpS6, anti-p70S6K T389 , anti-p70S6K, anti-LC3B, anti-HSP90, anti-PTEN, anti-AKT S473 , anti-AKT, anti-4EBP1, and anti-RAPTOR antibodies were from Cell Signalling Technologies. Anti-β -actin antibody was from Sigma and anti-TSC2 from Thermo Scientific (MA5-15004). Densitometry-based quantification was performed using ImageJ software. For half-life assays, DU145 cells stably expressing the indicated constructs were challenged with CHX (5 μ g ml −1
) and protein was extracted at the indicated time points (cells were treated with vehicle (DMSO), MG132 (5 μ M), or Torin-1 (250 nM) 120 min before CHX challenges when indicated). Anchorage-independent growth assays were performed as previously described 39 , seeding 3000 (PC3) or 5000 (DU145) cells per well. RNA was extracted using a NucleoSpin RNA isolation kit from Macherey-Nagel (740955.240C). One microgram of total RNA was used for complementary DNA (cDNA) synthesis using qScript cDNA Supermix from Quanta (95048). Quantitative PCR (qPCR) was performed as previously described 38 . Applied Biosystems TaqMan probes were as follows: Amd1/AMD1 (Mm04207265, Hs00750876s1), β-ACTIN/β-Actin (Hs99999903_m1/Mm00607939_s1), and GAPDH/Gapdh (Hs02758991_ g1/Mm99999915_g1). Universal Probe Library (UPL, Roche) probes were as follows: AMD1 (probe 72, primer F: CAGACCTCCTATGATGACCTGA; primer R: TCAGGTCACGAATTCCACTCT), Odc1 (probe 80, primer F: GCTAAGTCG ACCTTGTGAGGA; primer R: AGCTGCTCATGGTTCTCGAT), ODC1 (probe 34, primer F: AAAACATGGGCGCTTACACT; primer R: TGGAATTGC TGCATGAGTTG), and Mtap (probe 12, primer F: CCATGGCAACCGACT ATGAT; primer R: AAACCCCATCCACTGACACT). Foci assays were performed seeding 500 cells per well (six-well plate) and staining and counting them by crystal violet after 10 days. Lentiviral and retroviral transductions were performed as previously described 34, 38 . Kinase assay. Human AMD1 variants (carboxy-terminal HA tag, non-processing mutant S229A; S298 (wild type) or S298A; details available upon request) were prepared by overlapping PCR and cloned as BamH1-Not1 into pGEX-6P-1 (GE Healthcare). Sequence-confirmed clones were induced with 1 mM IPTG (isopropyl-β -d-thiogalactoside) for 16 h at 20 °C in C41 (DE3) pLysS (Lucigen). GST fusion proteins were purified first by glutathione affinity chromatography (eluted in 40 mM reduced glutathione; 25 mM HEPES pH 8; 50 mM KCl; 0.1% BME buffer) and then separated by gel filtration chromatography. Proteins were concentrated by ultrafiltration (Vivaspin 5K MWCO cut-off; Sartorius) and used for kinase assays.
Endogenous mTORC1 complex was immunoprecipitated from HEK293 cells using anti-Raptor antibody (S682B, fourth bleed, https://mrcppureagents. dundee.ac.uk/) coupled to Protein G Sepharose beads (Amersham). The cells were stimulated with IGF (50 ng ml −1 ) for 20 min before lysis in mTORC1 lysis buffer (40 mM HEPES pH 7.4, 120 mMNaCl, 1 mM EDTA, 0.3% (w/v), CHAPS, 10 mM Na-pyrophosphate, 10 mM Na-glycerophosphate, 1 mM Na-orthovanadate, protease inhibitor cocktail (Roche)). The immunoprecipitate was washed twice with mTORC1 lysis buffer, containing 0.5 M NaCl, twice with mTORC1 lysis buffer, and twice with mTORC1 kinase assay buffer (25 mM HEPES pH 7.4, 50 mMKCl). The substrates were added to immunoprecipitate in kinase assay buffer (15 μ l) before adding the 10 μ l of the ATP mixture (10 mM MnCl 2 , 100 μ M ATP, 1 μ Ci [γ -32 P]ATP in kinase buffer). The reaction was performed in a thermomixer at 30 °C for 30 min and was terminated by adding the 4× sample buffer (NuPAGE LDS sample buffer, Life Technologies). The reaction mixture was loaded on gel. Dried gel was exposed to X-ray films (Amersham). One microlitre of reaction mixture was loaded on gel for immunoblot analysis. GST-S6K D236A (DU32609, https://mrcppureagents.dundee.ac.uk/) was purified from HEK293 cells pretreated with 0.1 μ M AZD-8055. The protein was purified using GST-Sepharose beads (Amersham) according to the manufacturer's instructions. Anti-Raptor (S682B, fourth bleed, https://mrcppureagents.dundee.ac.uk/), anti-phospho-S6K1 T389 (9205, Cell Signaling Technology), anti-GST (S902A, third bleed, https://mrcppureagents.dundee.ac.uk/). Immunohistochemical analysis. Histochemical analysis by haematoxylin and eosin, anti-RpS6 S235/6 , anti-Akt S473 (Cell Signaling Technology), and Pten (51-2400) immunostaining was performed as previously described 40, 41 . Immunohistochemical analysis of AMD1 (Proteintech, dilution 1/100) was performed using DAKO EnVision FLEX High pH (DAKO). The scoring system was based on the quantification of the percentage of cells' negative, low (1+ ), medium (2+ ), or high (3+ ) immunoreactivity. Subsequently, the H score was calculated as follows: H = (percentage of cells 1+ ) + (2 × (percentage of cells 2+ )] + [3 × (percentage of cells 3+ )). Differential H score was calculated as Δ H = H on treatment − H pre-treatment . Metabolomic analysis. For in vitro metabolomic analysis, growing cells were washed with ammonium carbonate pH 7.4 and snap-frozen in liquid nitrogen. Metabolites were extracted from cells or tissues with cold 80/20 (v/v) methanol/ water. Samples were then dried and stored at − 80 °C until MS analysis. Highthroughput time-of-flight analysis was conducted using flow injection analysis as previously described 42 . In short, samples were re-suspended and injected on an Agilent 1100 coupled with an Agilent 6520 QToF mass spectrometer with an electrospray ionization source. The mobile phase consisted of 60/40 methanol/ water with 0.1% formic acid and was used to deliver 2 μ l of each sample to the MS, flowing at 150 μ l min . Data were collected in positive mode with 4 GHz HiRes resolving power with internal lock masses. Data processing was conducted with Matlab R2010b. Relative cell number or protein amount was used for normalization.
Quantitative LC/MS was conducted as previously described 43 . A ThermoAccela 1250 pump delivered a gradient of 0.025% heptafluorobutyric acid, 0.1% formic acid in water and acetonitrile at 400 μ l min −1 . The stationary phase was an Atlantis T3, 3 μ m, 2.1 mm × 150 mm column. A QExactive mass spectrometer was used at 70,000 resolving power to acquire data in full-scan mode. Data analysis was conducted in MAVEN 44 and Spotfire. Peak areas derived from stable isotope labelling experiments were corrected for naturally occurring isotope abundance.
For plasma [
13 C]methionine analysis, blood samples from mice were extracted at the indicated times, transferred at room temperature to heparinized collection tubes, and centrifuged at 13,000 r.p.m. and 4 °C for 10 min. Plasma was transferred to fresh tubes and processed for ultra-high-performance LC coupled to mass spectrometry (UPLC-MS) analysis. Briefly, to 40 μ l aliquots of mouse plasma, 40 μ l of water/0.15% formic acid was added. Subsequently, proteins were precipitated by addition of 120 μ l of acetonitrile. To optimize extraction, after addition of acetonitrile, the samples were sonicated for 10 min at 4 °C and agitated at 1,400 r.p.m. for 30 min at 4 °C. Next, the samples were centrifuged at 14,000 r.p.m. for 30 min at 4 °C. The supernatant was transferred to a fresh vial and measured with a UPLC system (Acquity, Waters, Manchester, UK) coupled to a time-offlight mass spectrometer (SYNAPT G2, Waters). A 2.1 mm × 100 mm, 1.7 μ m BEH AMIDE column (Waters), thermostated at 40 °C was used for the assay. Solvent A (aqueous phase) consisted of 99.5% water, 0.5% formic acid, and 20 mM ammonium formate, while solvent B (organic phase) consisted of 29.5% water, 70% MeCN, 0.5% formic acid, and 1 mM ammonium formate. To obtain a good separation of the analytes, the following gradient was used: from 5% A to 50% A in 2.4 min in curved gradient (number 8, as defined by Waters), from 50% A to 99.9% A in 0.2 min constant at 99.9% A for 1.2 min, back to 5% A in 0.2 min. The flow rate was 0.250 ml min −1 and the injection volume was 2 μ l. All samples were injected randomly and analytes were measured in enhanced duty cycle mode, optimized for the mass of the analyte in question. Methionine and [ Polysome profiling. Distribution of mRNAs across sucrose gradients was performed as described earlier 45 , except for minor modifications. Phosphoproteomic analysis of AMD1. DU145 cells stably expressing Myc-AMD1-HA were plated in two or three 150 mm plates per condition to ensure a final density no higher than 50-60% and sufficient protein amounts to immunoprecipitate ectopic AMD1 (using agarose HA-beads, Sigma, according to the manufacturer's instructions). Cells were treated for 6 h with rapamycin (20 nM) and Torin-1 (250 nM) before immunoprecipitation. Protein eluates from the immunoprecipitated samples were separated by SDS-PAGE. The bands corresponding to AMD1 and the pro-enzyme were visualized using Sypro-Ruby (Invitrogen), excised, and in-gel digested with trypsin. The resulting peptides were analysed by LC-MS/MS using an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific). Raw files were searched against a Uniprot Homo sapiens database (20,187 sequences) using Sequest-HT as the search engine through the Proteome Discoverer 1.4 (Thermo Scientific) software. Peptide identifications were filtered by Percolator at a false discovery rate of 1% using the target-decoy strategy. Label-free quantification was performed with MaxQuant, and extracted ion chromatograms for AMD1 phosphopeptides were manually validated in Xcalibur 2.2 (Thermo). Bioinformatic analysis. All the data sets used for the data mining analysis [46] [47] [48] [49] were downloaded from the Gene Expression Omnibus, and subjected to background correction, log 2 transformation, and quartile normalization. In the case of using a pre-processed data set, this normalization was reviewed and corrected if required. Statistical analysis. No statistics were applied to determine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Data analysed by parametric tests are represented by the mean ± s.e.m. of pooled experiments; for non-parametric tests, the median with interquartile range is depicted, unless otherwise stated. Values of n represent the number of independent experiments performed or the number of individual mice or patient specimens. For each independent in vitro experiment, at least three technical replicates were used and a minimum number of three experiments were performed to ensure adequate statistical power. Analysis of variance was used for multi-component comparisons and Student's t-test for two-component comparisons. In the in vitro experiments, normal distribution was confirmed or assumed (for n < 5). Two-tailed statistical analysis was applied for experimental design without predicted result, and one-tailed analysis for validation or hypothesis-driven experiments. The confidence level used for all the statistical analyses was 0.95 (α = 0.05). Data availability. The authors declare that data supporting the findings of this study are available within the paper and its supplementary information files. Source data for unprocessed scans and Fig. 2d and Extended Data Figs 3d, q-s and 4i are provided with the paper.
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Extended Data Figure 5 | PTEN-PI3K-mTORC1-dependent regulation  of AMD1 in prostate cancer. a, b , Amd1 protein quantification from Fig. 3a (a, n = 3 = 3 independent experiments) . e, Schematic representation of the PI3K signalling pathway and the pharmacological/genetic tools used in this study. f, ProAMD1 and AMD1 protein quantification from Fig. 3b (sample number as indicated by dots) . g, AMD1 gene expression upon treatment (24 h) with vehicle (V, DMSO), rapamycin (R, 20nM) and Torin-1 (T, 250 nM for PC3 and DU145, 125 nM for LNCaP) (LNCaP, n = 8 for Torin-1 and n = 6 for rapamycin; PC3 and DU145, n = 6 independent experiments as indicated by dots). Mean ± s.e.m. h, Representative western blot analysis of AMD1 levels upon 24-h treatment of DU145 cells with vehicle, Torin-1 (mTORC1/2 inhibitor; 250 nM), PD032901 (ERK-MAPK inhibitor, PD; 100 nM), SP600125 (JNK-SAPK inhibitor, SP; 10 μ M), and SB203580 (p38-MAPK inhibitor, SB; 5 μ M) (n = 3 independent experiments). i, Impact of inducible RAPTOR silencing in DU145 cells on proAMD1 protein levels (doxycycline-induced, 250 ng ml −1 ) (representative experiment out of n = 6). j, Impact of inducible TSC2 silencing in DU145 cells on proAMD1 protein levels (doxycycline-induced, 250 ng ml −1 ) (representative experiment out of n = 6). * P < 0.05; * * P < 0.01; * * * P < 0.001. Red asterisk in western blots indicates non-specific band. Arrows indicate specific immunoreactive bands. Student's t-test (c, f, g ) and Mann-Whitney test (a, b).
